Literature DB >> 18489242

Extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bulgarian hospitals.

Rumyana Markovska1, Ines Schneider, Emma Keuleyan, Mariya Sredkova, Dobrinka Ivanova, Boyka Markova, Grozdanka Lazarova, Elisaveta Dragijeva, Encho Savov, Irina Haydouchka, Nasya Hadjieva, Lena Setchanova, Ivan Mitov, Adolf Bauernfeind.   

Abstract

The aim of the study was to describe the emergence, the spread, and the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Bulgaria. Over eight years (1996-2003), 442 ESBL-screen-positive isolates were collected in nine medical institutions in four Bulgarian towns. Class A ESBLs of the SHV, TEM, and CTX-M groups were identified in seven species. SHV-type enzymes persisted during the whole study period, TEM-ESBLs appeared first in 1999, and CTX-M-types appeared first in 2001. The rate of CTX-M enzyme producers increased rapidly between 2001 and 2003, while the rate of SHV producers decreased. Six different ESBL-types were identified, namely, SHV-2, -5, and -12, CTX-M-3 and -15, and a new TEM-3-like variant (TEM-139). The most widespread enzymes were SHV-12, CTX-M-15, and CTX-M-3 found in seven centers. TEM-139 was identified mainly in one center. A trend for strains harboring more than one ESBL gene, for example, CTX-M + SHV, was observed since 2002. Plasmid fingerprinting and random amplified polymorphic DNA analysis typing revealed wide dissemination of identical plasmids among different bacterial species and hospitals, as well as clonal spread of ESBL producers. Our data contribute to clarify the dynamics in the prevalence of ESBLs in Bulgaria and demonstrate the importance of molecular procedures for their analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489242     DOI: 10.1089/mdr.2008.0814

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

1.  Detection of CMY-99, a novel acquired AmpC-Type β-lactamase, and VIM-1 in Proteus mirabilis isolates in Bulgaria.

Authors:  Ines Schneider; Rumyana Markovska; Ylia Marteva-Proevska; Ivan Mitov; Boyka Markova; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

2.  New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.

Authors:  Ines Schneider; Anne Marie Queenan; Rumyana Markovska; Boyka Markova; Emma Keuleyan; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

3.  Evaluation of antimicrobial resistance among Salmonella and Shigella isolates in the University Hospital "St. George," Plovdiv, Bulgaria.

Authors:  Michael M Petrov; Atanaska Petrova; Irina Stanimirova; Marina Mircheva-Topalova; Lalka Koycheva; Rayna Velcheva; Mariana Stoycheva-Vartigova; Ralitsa Raycheva; Galina Asseva; Petar Petrov; Velichka Kardjeva; Marianna Murdjeva
Journal:  Folia Microbiol (Praha)       Date:  2016-10-19       Impact factor: 2.099

4.  Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital.

Authors:  Didier Schoevaerdts; Pierre Bogaerts; Alexandre Grimmelprez; Marie de Saint-Hubert; Bénédicte Delaere; Jacques Jamart; Christian Swine; Youri Glupczynski
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

5.  Molecular characterization of bacteremic Escherichia coli isolates in Romania.

Authors:  Codruţa-Romaniţa Usein; Raluca Papagheorghe; Mihaela Oprea; Maria Condei; Monica Strãuţ
Journal:  Folia Microbiol (Praha)       Date:  2015-10-09       Impact factor: 2.099

6.  Molecular Analysis of Antibiotic Resistance Determinants and Plasmids in Malaysian Isolates of Multidrug Resistant Klebsiella pneumoniae.

Authors:  Farah Al-Marzooq; Mohd Yasim Mohd Yusof; Sun Tee Tay
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.